- Home
- OS vs UPB Comparison
OS vs UPB Comparison
Compare OS & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OS
- UPB
- Stock Information
- Founded
- OS 2012
- UPB 2021
- Country
- OS United States
- UPB United States
- Employees
- OS N/A
- UPB N/A
- Industry
- OS
- UPB
- Sector
- OS
- UPB
- Exchange
- OS NYSE
- UPB NYSE
- Market Cap
- OS 7.1B
- UPB 1.0B
- IPO Year
- OS 2024
- UPB 2024
- Fundamental
- Price
- OS $28.29
- UPB $16.81
- Analyst Decision
- OS Strong Buy
- UPB Strong Buy
- Analyst Count
- OS 19
- UPB 4
- Target Price
- OS $35.67
- UPB $56.50
- AVG Volume (30 Days)
- OS 1.1M
- UPB 470.1K
- Earning Date
- OS 02-15-2025
- UPB 02-14-2025
- Dividend Yield
- OS N/A
- UPB N/A
- EPS Growth
- OS N/A
- UPB N/A
- EPS
- OS N/A
- UPB N/A
- Revenue
- OS $459,526,000.00
- UPB $2,207,000.00
- Revenue This Year
- OS $33.26
- UPB N/A
- Revenue Next Year
- OS $20.42
- UPB N/A
- P/E Ratio
- OS N/A
- UPB N/A
- Revenue Growth
- OS 64.51
- UPB 82.10
- 52 Week Low
- OS $24.50
- UPB $14.97
- 52 Week High
- OS $35.39
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- OS N/A
- UPB N/A
- Support Level
- OS N/A
- UPB N/A
- Resistance Level
- OS N/A
- UPB N/A
- Average True Range (ATR)
- OS 0.00
- UPB 0.00
- MACD
- OS 0.00
- UPB 0.00
- Stochastic Oscillator
- OS 0.00
- UPB 0.00
About OS ONESTREAM INC
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.